Umesolerbart is a humanized IgG4 kappa monoclonal antibody specifically targeting Bet v 1, the major allergenic protein in birch pollen. It binds to Bet v 1 to neutralize its allergenicity, preventing IgE-mediated cross-linking on mast cells and basophils. It is being developed for the treatment of birch pollen allergy, aiming to reduce allergic symptoms such as rhinitis, conjunctivitis, and asthma exacerbations during pollen season.